Just a few days after NexImmune bumped up its credentials with the hiring of Gilead Sciences and Kite Pharma alum Robert Knight, M.D., the T-cell biotech is now gunning for an $86 million IPO.
The startup wants the cash to boost its work on immunotherapy, with its platform designed to employ the body’s own T cells to generate a potent and durable immune response that mimics natural biology.
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases,” the Maryland biotech said in its Securities and Exchange Commission filing.
Read the full article at FierceBiotech
Latest posts by BioBuzz Media (see all)
- Federal Realty Plans 10-Story Life Science Facility at Pike & Rose to Fuel Extension of Montgomery County’s Life Science and Biotech Corridor to North Bethesda - December 1, 2021
- BioHealth Capital Region Spotlight: Creative Bio-Peptides Awarded $5.78 from NIH to Develop Breakthrough Treatments for Neuroinflammatory/Neurodegenerative Indications - November 30, 2021
- IndyGeneUS AI, Inc. to Acquire the World’s First Blockchain-Mediated Free Market For Genetic Data, EncrypGen - November 29, 2021
- NeuExcell Therapeutics, Inc. Signs Lease with The Discovery Labs to Establish Corporate Headquarters in the Philadelphia Region - November 23, 2021
- Red Cell Forms Zephyr AI to Revolutionize Drug Discovery and Precision Medicine - November 23, 2021